Comparison of in vitro biological properties and mouse toxicities of three thymidine analogs active against human immunodeficiency virus.
Three analogs of thymidine, D4T [2',3'-didehydro-2',3'-dideoxythymidine; 1-(2,3-dideoxy-beta-D-glyceropent-2-enofuranosyl)thymine], FddT (3'-fluoro-3'-deoxythymidine), and AZT (3'-azido-3'-deoxythymidine), were compared in biological tests designed to assess their potential utility as anti-human immunodeficiency virus (HIV) agents. The in vitro potencies of these compounds against HIV infection in CEM cells were measured, with FddT and AZT being more potent than D4T. The cytotoxicities of D4T, FddT, and AZT for CEM cells were comparable. The triphosphates of these three derivatives inhibited purified HIV reverse transcriptase, and their affinities for this polymerase were found to be 1 or 2 orders of magnitude greater than that for the normal substrate, dTTP. D4T was less toxic than FddT or AZT for cultured human and mouse bone marrow cells (granulocyte-macrophage CFU). The three compounds had similar toxicities for human progenitor erythrocyte burst-forming units. In a 30-day mouse toxicity study, AZT and FddT produced a similar spectrum of hematopoietic toxicities. These toxic effects occurred at much lower doses of FddT than of AZT. At the higher doses of FddT, a significant incidence of lethality occurred. By contrast, D4T was considerably less toxic than both AZT and FddT in this study. The dose-limiting toxicity of D4T in mice was hepatotoxicity. The very different phosphorylation patterns of D4T, its lower toxicity, and its comparable potency relative to FddT and AZT suggest that the potential of D4T as an anti-HIV agent should be further explored.
Department of Antiinfective Chemistry, Bristol-Myers Squibb Company, Wallingford, Connecticut 06492-7660.
M M
MM
Mansuri
M J
MJ
Hitchcock
R A
RA
Buroker
C L
CL
Bregman
I
I
Ghazzouli
J V
JV
Desiderio
J E
JE
Starrett
R Z
RZ
Sterzycki
J C
JC
Martin
D000284:Administration, Oral; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use* / Q000633:toxicity; D001853:Bone Marrow / Q000187:drug effects; D015224:Dideoxynucleosides / Q000627:therapeutic use* / Q000633:toxicity; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology; D007942:Leukemia, Experimental / Q000097:blood / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D012190:Retroviridae / Q000187:drug effects; D018894:Reverse Transcriptase Inhibitors; D018119:Stavudine; D015215:Zidovudine / Q000627:therapeutic use* / Q000633:toxicity
D000998:Antiviral Agents; D015224:Dideoxynucleosides; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D018119:Stavudine; C002854:alovudine